SHANGHAI and SAN DIEGO and HANGZHOU, China, Nov. 17, 2021 — Inmagene Biopharmaceuticals (“Inmagene” or the “Company”) announced that it has filed two international patent applications for its drug candidates, IMG-007 (OX40 antagonist) and IMG-008 (IL-36R antagonist). One application covers IMG-008’s molecular sequence and the other covers improved development in IMG-007’s formulation. Inmagene controls the global rights to develop and commercialize both drug candidates.
These are the first of a series of patent applications being prepared by Inmagene, demonstrating the Company’s strong innovation capabilities. Guided by global scientific and clinical intelligence, leveraging the potential for China’s high-efficiency drug development resources, Inmagene is advancing 12 “smart” innovation programs, creating new drug candidates, such as IMG-008, from scratch.
About IMG-007 (OX40 antagonist)
IMG-007, an antibody targeting OX40, is a drug candidate for autoimmune diseases, such as graft versus host disease, asthma, atopic dermatitis, rheumatoid arthritis and inflammatory bowel disease. Preclinical trial data has demonstrated that IMG-007 has superior activity as compared to a leading competitor. IMG-007, in-licensed from HUTCHMED (Nasdaq/AIM: HCM), is under CMC and toxicological development and the Company plans to submit IMG-007’s IND application by the first half of 2022.
About IMG-008 (IL-36R antagonist)
IMG-008, internally-created by Inmagene, is an antibody targeting IL-36R. It is a drug candidate for autoimmune diseases, including palmoplantar pustulosis, ichthyosis, hidradenitis suppurativa, atopic dermatitis, inflammatory bowel disease and generalized pustular psoriasis. Preclinical results have demonstrated that IMG-008 has a longer half-life, higher exposure, and stronger activity as compared to a leading competitor. The Company plans to submit IMG-008’s IND application in the second half of 2022.